A study that examined two Italian cohorts showed that IBD carriers of the PNPLA3 148M allele have a higher risk of hepatic steatosis (odds ratio of 2.9) and higher biomarkers of liver damage [115] (Table 2). This evidence concerns the gene PNPLA3 and irritable bowel syndrome.